Pfizer's Ibrance Fails To Extend Overall Survival In Newly Diagnosed Breast Cancer Setting

  • Pfizer Inc PFE announced overall survival (OS) results from the Phase 3 PALOMA-2 trial of Ibrance (palbociclib) combined with Novartis AG's NVS Femara (letrozole) in breast cancer setting compared to placebo.
  • After a median follow-up of seven and a half years, Ibrance/Femara combo failed to extend the lives of those breast cancer patients compared with Femara alone.
  • Patients on the Ibrance-Femara combo lived a median of 53.9 months versus 51.2 months for those in the solo Femara group. 
  • PALOMA-2 met its primary endpoint of progression-free survival (PFS) in 2016 and was published in The New England Journal of Medicine in November 2016. 
  • The results demonstrated that Ibrance plus letrozole resulted in an improved median PFS of 24.8 months compared to 14.5 months with placebo plus letrozole (HR=0.580). 
  • The trial also showed that in addition to substantially delaying progressive disease, Ibrance as a first-line treatment, combined with letrozole, delayed the time to chemotherapy (38.1 months vs. 29.8 months).
  • Price Action: PFE shares closed higher by 0.95% at $53.18 on Friday.

Posted In: BriefsBiotechLarge CapNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.